Müller-Bühl U, Diehm C, Scheuermann W, Mörl H
Dtsch Med Wochenschr. 1983 Nov 25;108(47):1795-7. doi: 10.1055/s-2008-1069828.
The effectiveness of a new, nifedipine-like calcium antagonist (Bay K 9320) on the severity and frequency of episodic digital vasospasms was studied in a randomized double-blind trial of 24 patients (10 women, 14 men) with Raynaud's phenomenon. During the winter months the patients took one tablet three times daily for three weeks, each tablet either containing 20 mg of the calcium antagonist or a placebo. Three patients had collagen disease, 21 a primary form of Raynaud's phenomenon. Subjective improvement was reported by nine of twelve patients receiving the drug, while no improvement occurred in nine patients on the placebo. Light-plethysmography demonstrated under calcium antagonist treatment a reduction in the cold-provoked acral blood flow decrease more than four-fold compared with the unchanged value in the placebo group.
在一项针对24名患有雷诺现象的患者（10名女性，14名男性）的随机双盲试验中，研究了一种新型硝苯地平样钙拮抗剂（Bay K 9320）对发作性手指血管痉挛的严重程度和发作频率的疗效。在冬季，患者每天服用一片药，分三次服用，持续三周，每片药要么含有20毫克钙拮抗剂，要么是安慰剂。3名患者患有胶原病，21名患有原发性雷诺现象。接受药物治疗的12名患者中有9名报告主观症状有所改善，而服用安慰剂的9名患者则无改善。光电容积描记法显示，与安慰剂组未改变的值相比，钙拮抗剂治疗下冷激发引起的手足血流减少超过四倍。
